Avenanthramide pillThe Dr. in charge of CSCI's clinical trial(Dr. Tardiff) helped with colchicine which recently became the first FDA approved anti-inflammatory treatement for heart disease. That drug has potential serious adverse events, however, and can kill if overdosed. It also has an unwelcome side-effect profile. CSCI's clinical trial was performed in a hospital and has shown no serious adverse events up to 960mg per day at a single dose or when two doses are given per day at three different dose levels tested.
It will be interesting to see the full details for safety/tolerability. The scientific community is pushing to treat heart disease at the earliest possible time and a natural neutraceutical option may be an ideal.